Very Popular Class of Drugs Now Suspected to be Connected to Dementia
#74 2023 The Rowen Report
Dear Subscriber,
I took a short break this past weekend. I was invited and honored to speak at. The Menlo Park Forum where Terri and I were greeted by a wonderful group of people interested in the trying times of our times. They wanted to hear about my recent experiences and updates on some issues of law and ozone therapy.
In the meantime, I came across this report. I think my long-term readers know of my sentiments about ridiculous studies of synthetic petrochemical pharmaceuticals suppressing a symptom (not curing) but also not addressing long term consequences of taking such snake oil. Well, here’s a case in point. Even the introduction of this abstract admits that studies do not examine the cumulative use of drugs, addressing this particular class- PPI or proton pump inhibitors, amongst the most used chemicals in American patients. Here you will see that long term use of PPI is related to a 33% increase in dementia!
Hmmm. Let’s think about it for a moment. Antacids are well known to be associated with an increased risk of osteoporosis. Why? They block a needed function of the stomach – to make acid. And Acid is necessary not only to digest protein but to free minerals for absorption. No acid, fewer minerals, including calcium, and hence less bone. This was a no brainer to me when these enzyme poisons first came out.
Well, we now see yet another possible long-term effect from suppressing body functions – PPI association with dementia. Mechanism? Doesn’t take a lot of thought. Proteins not digested fully, which might lead to allergens and immune reactive forms of proteins coming into the blood stream. Reduction of minerals might not only defeat bone formation but why not also impair other organs, including the brain!
To me, this should be a another wake up call to the use of ALL drugs. We have a totally corrupt system where the Fraud and Deception Administration “approves” some chemical that white washes a symptom, like upset stomach, and causes consequences, perhaps disastrous, in other parts of the body. Our body is like a balloon. If you press the balloon in one place, the pressure inside has to go somewhere, affecting other parts of the balloon.
I consider hypertension to have actual causes. Could be deficiency of minerals, essential fatty acids, reactions to toxic foods, ingestion of fried foods, deficiency of critical bioflavonoids, stress, laziness (lack of exercise) , and much more. How do we know that high blood pressure is not the result of the body needing a higher pressure to move blood to oxygen starved cells. Take the drug rather than address causes and you might cause very serious consequences downstream. Studies are not done to look at this. Same issues with vaccines in children.
This is a class of drugs I have never recommended, used or prescribed. Same with statins. We are messing with God’s Divine creation when inhibiting the functions the Creator placed in our bodies to make them hummm. Consider the consequences of fluoride in water of iron fortification of food. Downstream consequences. Sometimes I cannot help but think ALL of this this is purposeful, just like the COVID scamdemic.
To Your Excellent Health,
Robert Jay Rowen, MD
Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study
Abstract
Background. Studies on the association between proton pump inhibitor (PPI) use and dementia report mixed results and do not examine the impact of cumulative PPI use. We evaluated the associations between current and cumulative PPI use and risk of incident dementia in the Atherosclerosis Risk in Communities (ARIC) Study.
Methods. These analyses used participants from a community-based cohort (ARIC) from the time of enrollment (1987-89) through 2017. PPI use was assessed via visual medication inventory at clinic Visits 1 (1987-89) to 5 (2011-13) and reported annually in study phone calls (2006-2011). The present study uses ARIC Visit 5 as baseline, since this was the first visit in which PPI use was common. PPI use was examined two ways: current use at Visit 5 and duration of use prior to Visit 5 (Visit 1 to 2011, exposure categories: 0 days, 1 day – 2.8yrs, 2.8-4.4yrs, >4.4yrs). The outcome was incident dementia after visit 5. Cox Proportional Hazard models were used, adjusted for demographics, co-morbid conditions, and other medication use.
Results. A total of 5,712 dementia-free participants at visit 5 (mean age 75.4±5.1 years; 22% Black race; 58% female) were included in our analysis. The median follow-up was 5.5 years. Minimum cumulative PPI use was 112 days and maximum use was 20.3 years. There were 585 cases of incident dementia over median follow up time. Participants using PPIs at Visit 5 were not at a significantly higher risk of developing dementia during subsequent follow-up than those not using PPIs (Hazard Ratio (HR): 1.1 [95% Confidence Interval (CI): 0.9-1.3]). Those who used PPIs for >4.4 cumulative years prior to Visit 5 were at 33% higher risk of developing dementia during follow-up (HR: 1.3 [95%CI: 1.0-1.8]) than those reporting no use. Associations were not significant for lesser amounts of PPI use.
Discussion. Future studies are needed to understand possible pathways between cumulative PPI use and the development of dementia.
Classification of Evidence. This study provides Class III evidence that use of prescribed PPIs for > 4.4 years by individuals ages 45 years and older is associated with a higher incidence of newly diagnosed dementia.
https://n.neurology.org/content/early/2023/08/09/WNL.0000000000207747
I can't give personal medical advice here. There are things such as aloe vera, certain licorice extracts and more that could help, but every person is different and must be evaluated individually. It might be foods. It might even be lack of acid that causes indigestion.
While looking for something else, I came upon this very interesting recent study, published last December, of a new use for the topical glaucoma eye drop prostaglandin analog brimatoprost:
Bimatoprost promotes satiety and attenuates body weight gain in rats fed standard or obesity-promoting diets.
Highlights
Skin administration of bimatoprost led to a dose dependent reduction in weight gain.
Application led to reduction of fat under the skin and systemically.
Systemic effect mediated by a decrease in food intake and gastric emptying.
Extends previously published findings of bimatoprost and prostamides on adiposity.
https://www.sciencedirect.com/science/article/pii/S0952327822001211
It's a very comprehensive study, and I suppose if it would work without significant forseen or unforeseen effects, as with antacids and protein pump inhibitors, it might be quite useful. However all the funding was provided by Allergan, an eye drop manufacturer:
Funding
The intramural program at Allergan Inc. provided all funds necessary to carry out the described studies, including at third parties.
Declaration of Competing Interest
Although no financial gain or loss is expected due to this publication, we feel it is important to declare the following: Neil Poloso, Warren Tong are employees of AbbVie. Neil Poloso, Warren Tong hold stock and/or stock options in AbbVie. Kerry Loomes received research funding from Allergan for work described in this manuscript.